Pharma major Bharat Biotech’s Covid-19 vaccine, Covaxin, is being administered through an injection in the country’s inoculation drive.
Now, the company has received a nod from India’s drug regulator to conduct phase 2 and 3 clinical trials of their against COVID-19.
The Department of Biotechnology said on Friday that early-stage trials of the vaccine candidate, BBV154, have been completed in subjects aged 18 to 60 years
“No serious adverse events reported. Previously, the vaccine was found to be safe, immunogenic and well tolerated in the pre-clinical toxicity studies. The vaccine was able to elicit a high level of neutralizing antibodies in animal studies,” the release said.
BBV154 is an intranasal replication-deficient chimpanzee adenovirus SARS-CoV-2 vectored vaccine. Bharat Biotech has in-licensed technology from Washington University in St Louis, USA.
The release of Kamal Haasan's Indian 2, directed by S. Shankar, seems to be facing…
The fans are eagerly waiting for updates of NTR's new films and this coming May…
Amidst the enthusiastic cheers of Malla Reddy Engineering College students, the second single of hero…
"Kalki 2898 AD" is creating quite a buzz as the most awaited visual spectacle of…
This friday another four new movies hit theaters yesterday. These included Telugu films like "Aa…
It is known that the Election Commission had already ordered political parties to refrain from…